Wells Fargo & Company Issues Positive Forecast for Revvity (NYSE:RVTY) Stock Price

Posted by Amy Steele on Feb 3rd, 2026

Revvity (NYSE:RVTY – Get Free Report) had its price target upped by analysts at Wells Fargo & Company from $107.00 to $110.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 2.82% from the company’s current price.

Several other brokerages also recently weighed in on RVTY. Weiss Ratings restated a “sell (d)” rating on shares of Revvity in a research report on Monday, December 29th. Barclays upped their price objective on shares of Revvity from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Tuesday. Guggenheim initiated coverage on Revvity in a research note on Wednesday, October 15th. They issued a “neutral” rating for the company. Jefferies Financial Group upped their target price on Revvity from $100.00 to $105.00 and gave the stock a “hold” rating in a report on Monday. Finally, Bank of America cut Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price target on the stock. in a report on Monday, December 15th. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Revvity has an average rating of “Hold” and a consensus price target of $110.82.

Check Out Our Latest Stock Analysis on Revvity

Revvity Trading Down 1.7%

Shares of Revvity stock opened at $106.98 on Tuesday. The company has a quick ratio of 1.44, a current ratio of 1.75 and a debt-to-equity ratio of 0.36. Revvity has a 12-month low of $81.36 and a 12-month high of $126.57. The company has a market capitalization of $12.13 billion, a price-to-earnings ratio of 53.76, a PEG ratio of 3.32 and a beta of 1.06. The firm’s 50-day moving average price is $104.09 and its two-hundred day moving average price is $95.52.

Revvity (NYSE:RVTY – Get Free Report) last posted its quarterly earnings results on Monday, February 2nd. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.55 by $0.15. The business had revenue of $772.06 million for the quarter, compared to analyst estimates of $759.81 million. Revvity had a net margin of 8.44% and a return on equity of 7.52%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the business posted $1.42 EPS. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. On average, analysts forecast that Revvity will post 4.94 earnings per share for the current fiscal year.

Revvity declared that its Board of Directors has approved a stock buyback plan on Monday, October 27th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to repurchase up to 8.7% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Revvity

Institutional investors and hedge funds have recently bought and sold shares of the stock. Byrne Asset Management LLC raised its position in shares of Revvity by 0.9% during the 4th quarter. Byrne Asset Management LLC now owns 11,138 shares of the company’s stock valued at $1,078,000 after buying an additional 100 shares in the last quarter. Trust Point Inc. lifted its position in Revvity by 3.8% in the fourth quarter. Trust Point Inc. now owns 3,215 shares of the company’s stock valued at $311,000 after purchasing an additional 117 shares during the last quarter. First National Advisers LLC lifted its position in Revvity by 0.8% in the third quarter. First National Advisers LLC now owns 15,023 shares of the company’s stock valued at $1,317,000 after purchasing an additional 125 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Revvity by 26.2% in the fourth quarter. Farther Finance Advisors LLC now owns 698 shares of the company’s stock worth $68,000 after purchasing an additional 145 shares during the last quarter. Finally, Mackenzie Financial Corp increased its stake in shares of Revvity by 1.7% in the third quarter. Mackenzie Financial Corp now owns 8,955 shares of the company’s stock worth $785,000 after buying an additional 154 shares during the period. 86.65% of the stock is owned by hedge funds and other institutional investors.

More Revvity News

Here are the key news stories impacting Revvity this week:

Positive Sentiment: Q4 results beat expectations — adjusted EPS $1.70 (vs. consensus ~ $1.55) and revenue $772.1M, up 5.9% year-over-year, showing improving top- and bottom-line momentum. Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates
Positive Sentiment: Company raised FY2026 guidance — EPS guidance of $5.35–$5.45 and ~ $3.0B revenue guidance that sit above Street estimates, signaling management confidence in diagnostics strength. Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter
Positive Sentiment: Immediate market reaction was positive as investors pushed the stock higher on the beat + outlook, supported by analyst notes highlighting the upside. Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript
Neutral Sentiment: Management call/transcripts and slide deck are available — useful for investors wanting detail on segment trends, margin drivers and cadence of growth. Revvity (RVTY) Q4 2025 Earnings Call Transcript
Neutral Sentiment: Valuation debate: recent share weakness has prompted DCF/analyst pieces arguing the stock may be attractive vs. intrinsic value, but opinions vary — this may support longer-term buyers more than short-term traders. Is Revvity (RVTY) Attractive After Recent Share Price Weakness And DCF Valuation Gap
Negative Sentiment: Headwinds remain in academic research funding, which could pressure parts of the business even as diagnostics performs well — a risk to sustaining growth across all segments. Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

About Revvity

(Get Free Report)

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.